213 related articles for article (PubMed ID: 14560776)
1. The myelodysplastic/myeloproliferative disorders: the interface.
Bennett JM
Hematol Oncol Clin North Am; 2003 Oct; 17(5):1095-100, v. PubMed ID: 14560776
[TBL] [Abstract][Full Text] [Related]
2. Focus on myeloproliferative diseases and myelodysplastic syndromes.
Van Etten RA; Shannon KM
Cancer Cell; 2004 Dec; 6(6):547-52. PubMed ID: 15607959
[No Abstract] [Full Text] [Related]
3. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
4. Myelodysplastic/myeloproliferative neoplasms.
Cazzola M; Malcovati L; Invernizzi R
Hematology Am Soc Hematol Educ Program; 2011; 2011():264-72. PubMed ID: 22160044
[TBL] [Abstract][Full Text] [Related]
5. [Chronic myelomonocytic leukemia (CMML): recent advances in molecular pathogenesis and treatment].
Harada Y; Harada H
Rinsho Ketsueki; 2016 Feb; 57(2):147-55. PubMed ID: 26935632
[TBL] [Abstract][Full Text] [Related]
6. Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults.
Zandberg DP; Huang TY; Ke X; Baer MR; Gore SD; Smith SW; Davidoff AJ
Haematologica; 2013 Apr; 98(4):584-90. PubMed ID: 23144192
[TBL] [Abstract][Full Text] [Related]
7. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
8. Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the SARS-CoV-2 pandemic.
Patnaik MM; Lasho T; Padron E; McCullough K; Al-Kali A; Tefferi A; Zeidan AM; Gangat N; Savona M; Steensma DP; Solary E
Am J Hematol; 2020 Aug; 95(8):E203-E208. PubMed ID: 32356322
[No Abstract] [Full Text] [Related]
9. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.
Cervera N; Itzykson R; Coppin E; Prebet T; Murati A; Legall S; Vey N; Solary E; Birnbaum D; Gelsi-Boyer V
Am J Hematol; 2014 Jun; 89(6):604-9. PubMed ID: 24595958
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of TET2 deletions in myeloid disorders: a fluorescence in situ hybridization analysis of 109 cases.
Klaus M; Psaraki A; Mastrodemou S; Pyrovolaki K; Mavroudi I; Kalpadakis C; Papadaki HA
Leuk Res; 2011 Mar; 35(3):413-5. PubMed ID: 21087791
[TBL] [Abstract][Full Text] [Related]
11. CMML: Clinical and molecular aspects.
Itzykson R; Duchmann M; Lucas N; Solary E
Int J Hematol; 2017 Jun; 105(6):711-719. PubMed ID: 28455647
[TBL] [Abstract][Full Text] [Related]
12. The relationship between the myelodysplastic syndromes and the myeloproliferative disorders.
Bain BJ
Leuk Lymphoma; 1999 Aug; 34(5-6):443-9. PubMed ID: 10492067
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic and myeloproliferative disorders in children.
Hasle H
Curr Opin Pediatr; 2007 Feb; 19(1):1-8. PubMed ID: 17224655
[TBL] [Abstract][Full Text] [Related]
14. RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.
Janssen JW; Steenvoorden AC; Lyons J; Anger B; Böhlke JU; Bos JL; Seliger H; Bartram CR
Proc Natl Acad Sci U S A; 1987 Dec; 84(24):9228-32. PubMed ID: 3122217
[TBL] [Abstract][Full Text] [Related]
15. Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome?
Michaux JL; Martiat P
Leuk Lymphoma; 1993 Jan; 9(1-2):35-41. PubMed ID: 8477199
[TBL] [Abstract][Full Text] [Related]
16. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
Tiu RV; Sekeres MA
Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
[TBL] [Abstract][Full Text] [Related]
17. Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia.
Wood BL
Clin Lab Med; 2007 Sep; 27(3):551-75, vii. PubMed ID: 17658407
[TBL] [Abstract][Full Text] [Related]
18. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
19. Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms.
Loghavi S; Wang SA
Surg Pathol Clin; 2019 Sep; 12(3):651-669. PubMed ID: 31352979
[TBL] [Abstract][Full Text] [Related]
20. Myeloid malignancies: mutations, models and management.
Murati A; Brecqueville M; Devillier R; Mozziconacci MJ; Gelsi-Boyer V; Birnbaum D
BMC Cancer; 2012 Jul; 12():304. PubMed ID: 22823977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
